<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="calcitonin gene-related peptide (CGRP) plays a key role in the" exact="migraine" post="pathophysiology. This study aimed to investigate its role in"/>
 <result pre="Plasma CGRP concentrations were measured by ELISA. Results: In the" exact="migraine" post="group, more patients required acute therapy, as compared to"/>
 <result pre="the other preventives. Conclusion: The plasma CGRP level can differentiate" exact="migraine" post="from non-migraine headache. It may also serve as a"/>
 <result pre="the therapeutic strategy since it is higher in patients requiring" exact="migraine" post="prevention and responsive to short-term topiramate treatment. These results"/>
 <result pre="practice for the diagnosis and treatment of pediatric migraine. pediatric" exact="migraine" post="calcitonin gene-related peptide plasma biomarker anti-migraine drugs topiramate fig-count:"/>
 <result pre="of medication for a certain time period ( 5). The" exact="migraine" post="associations such as abdominal pain, limb pain, and motion"/>
 <result pre="The migraine associations such as abdominal pain, limb pain, and" exact="motion sickness" post="are common in children ( 6) but less in"/>
 <result pre="there are limited reports on the efficacy and safety of" exact="migraine" post="medications in the pediatric group. Only a few randomized"/>
 <result pre="CGRP has been shown to play a causative role in" exact="migraine" post="attacks since its level is shown to be elevated"/>
 <result pre="attacks since its level is shown to be elevated during" exact="migraine" post="attacks ( 10). Thus, CGRP is believed to be"/>
 <result pre="Thus, CGRP is believed to be a potential biomarker of" exact="migraine" post="( 11– 21). Pre-clinical studies have shown that trigeminal"/>
 <result pre="( 22– 24), resulting in pia vessel dilatation, leading to" exact="migraine" post="( 17). Moreover, CGRP antagonists can reduce cortical spreading"/>
 <result pre="which is believed to be an important pathogenic manifestation of" exact="migraine" post="with aura ( 18, 20, 21), in animal models"/>
 <result pre="considerably higher than those in healthy controls ( 15). During" exact="migraine" post="attacks, plasma CGRP levels are elevated in both adult"/>
 <result pre="CGRP receptor antagonist, olcegepant (BIBN4096BS), is effective in treating acute" exact="migraine" post="attacks ( 16) and anti-CGRP or anti-CGRP receptor monoclonal"/>
 <result pre="and anti-CGRP or anti-CGRP receptor monoclonal antibodies are approved for" exact="migraine" post="prevention ( 25, 26). Third, triptans, clinically effective anti-migraine"/>
 <result pre="of the plasma CGRP level in pediatric migraine, especially during" exact="migraine" post="attack ( 19). The present study further explored whether"/>
 <result pre="below 12 years and had never taken any medicine for" exact="migraine" post="prevention. There were 68 patients with migraine, 30 patents"/>
 <result pre="headache and 22 non-headache control subjects. The diagnosis of pediatric" exact="migraine" post="was based on the criteria of the International Classification"/>
 <result pre="compliance in children and the intent to seek for efficient" exact="migraine" post="preventives, we measured the short-term therapeutic response for at"/>
 <result pre="IL). Results Plasma samples were collected from 68 patients with" exact="migraine" post="(28 boys) aged 5–18 years (mean age, 11.7 ±"/>
 <result pre="response to each drug ( p &amp;gt; 0.05). In the" exact="migraine" post="group, 91% (62 out of 68 patients) required acute"/>
 <result pre="and Migraine Treatment Plasma CGRP levels were significantly different among" exact="migraine" post="(during or between attacks), non-migraine headache, and non-headache control"/>
 <result pre="that plasma CGRP is a potential diagnostic biomarker for pediatric" exact="migraine" post="( 19). Furthermore, a relatively higher plasma CGRP level"/>
 <result pre="CGRP level to serve as a biomarker guiding the pediatric" exact="migraine" post="treatment, which has never been mentioned before. According to"/>
 <result pre="in pain relief in a double-blind cross-over study of childhood" exact="migraine" post="( 28). The response rate of acetaminophen (42%) in"/>
 <result pre="that even as a second-line drug of choice for acute" exact="migraine" post="treatment, NSAIDs are better than acetaminophen (response rate: 56"/>
 <result pre="be not significantly superior to placebo in a trial on" exact="migraine" post="in Finland children ( 30). However, it was effective"/>
 <result pre="younger than 10 year old as a first-line choice for" exact="migraine" post="headache ( 31). Only one-third of patients here responded"/>
 <result pre="approved by the United States Food and Drug Administration for" exact="migraine" post="prevention for adults ( 33), is the highest (75%)."/>
 <result pre="drugs in this study. The effectiveness of beta-blockers for pediatric" exact="migraine" post="remains controversial ( 35– 37). This study shows that"/>
 <result pre="the findings of Bidabadi and Mashouf ( 38) in pediatric" exact="migraine" post="prophylaxis. The effectiveness of gabapentin in pediatric migraine has"/>
 <result pre="in pediatric migraine prophylaxis. The effectiveness of gabapentin in pediatric" exact="migraine" post="has rarely been studied ( 33, 39). The present"/>
 <result pre="use of gabapentin was found to be ineffective in adult" exact="migraine" post="treatment ( 40). The present study showed that plasma"/>
 <result pre="study showed that plasma CGRP can significantly differentiate children with" exact="migraine" post="from non-headache controls as well as from non-migraine headache."/>
 <result pre="that the recruited patients with relatively more severe or frequent" exact="migraine" post="headaches who need either acute or preventive therapy in"/>
 <result pre="acute therapy. It is interesting that disability, evaluated by pediatric" exact="migraine" post="assessment score (PedMIDAS), tended to be higher in patients"/>
 <result pre="could be a biomarker helping in the diagnosis of chronic" exact="migraine" post="in adults, whose pain pathways become sensitized after repeated"/>
 <result pre="with higher plasma CGRP levels may suffer from more frequent" exact="migraine" post="attacks, which may cause disability and require preventive therapy."/>
 <result pre="biomarker not only for determining the severity or chronicity of" exact="migraine" post="( 19, 42) but also for predicting the need"/>
 <result pre="0.81 and specificity 0.75 in predicting the diagnosis of pediatric" exact="migraine" post="in our previous study ( 19). Topiramate was developed"/>
 <result pre="anti-epileptic drug and was also found to be effective in" exact="migraine" post="prevention ( 45). Multi-center, randomized, double-blind, placebo-controlled trials established"/>
 <result pre="of topiramate in significantly reducing the frequency and severity of" exact="migraine" post="attacks in adults ( 46, 47). Topiramate also showed"/>
 <result pre="several open-label or randomized, double-blind, placebo-controlled studies in children with" exact="migraine" post="( 48, 49). However, its exact anti-migraine mechanism(s) remain"/>
 <result pre="inhibition of neurogenic dural vasodilatation ( 50). Pre-clinical studies in" exact="migraine" post="animal models have shown that topiramate inhibited neurogenic dural"/>
 <result pre="and dura ( 23, 24) of rats in a capsaicin-stimulated" exact="migraine" post="model ( 22). Topiramate has been also reported to"/>
 <result pre="were recently identified to be a novel drug target for" exact="migraine" post="treatment ( 23). It remains to be elucidated whether"/>
 <result pre="that the prophylactic effect of topiramate is mediated by a" exact="suppression" post="of CGRP release, which is a marker of trigeminal"/>
 <result pre="a potential biomarker for guiding the drug of choice for" exact="migraine" post="prevention. Some limitations of this study need to be"/>
 <result pre="cause body weight loss in some patients ( 55) and" exact="obesity" post="has been highlighted to be significantly associated with headache"/>
 <result pre="this study suggest that the plasma CGRP level can differentiate" exact="migraine" post="from non-migraine headache conditions in pediatric patients. It may"/>
 <result pre="of CGRP was significantly higher in pediatric migraineurs who required" exact="migraine" post="prophylaxis and were topiramate-responsive. Our results also suggest that"/>
 <result pre="into the clinical practice for the diagnosis and treatment of" exact="migraine" post="in children. Author Contributions P-CF designed and conducted experiments,"/>
 <result pre="References References 1. Goadsby PJ . Recent advances in understanding" exact="migraine" post="mechanisms, molecules and therapeutics. Trends Mol Med. ( 2007)"/>
 <result pre="1545– 602. 10.1016/S0140-6736(16)31678-6 27733282 4. Silberstein SD . Current management:" exact="migraine" post="headache. CNS Spectr. ( 2017) 22: 1– 13. 10.1017/S1092852917000864"/>
 <result pre="Gentile S et al. . Migraine equivalents as part of" exact="migraine" post="syndrome in childhood. Pediatr Neurol. ( 2014) 51: 645–"/>
 <result pre="25155656 7. Silberstein SD . Practice parameter: evidence-based guidelines for" exact="migraine" post="headache (an evidence-based review): report of the Quality Standards"/>
 <result pre="Papetti L Rubio-Beltran E et al. . Blocking CGRP in" exact="migraine" post="patients—a review of pros and cons. J Headache Pain"/>
 <result pre="al. . Vasoactive peptide levels in the plasma of young" exact="migraine" post="patients with and without aura assessed both interictally and"/>
 <result pre="Olajos S Jakab B Nemeth J et al. . NO-induced" exact="migraine" post="attack: strong increase in plasma calcitonin gene-related peptide (CGRP)"/>
 <result pre="receptor antagonist BIBN 4096 BS for the acute treatment of" exact="migraine" post=". N Engl J Med. ( 2004) 350: 1104–"/>
 <result pre="10.1111/j.1468-2982.2008.01816.x 19236383 20. Ayata C . Cortical spreading depression triggers" exact="migraine" post="attack: pro. Headache ( 2010) 50: 725– 30. 10.1111/j.1526-4610.2010.01647.x"/>
 <result pre="Different trigemino-vascular responsiveness between adolescent and adult rats in a" exact="migraine" post="model . Cephalalgia ( 2012) 32: 979– 90. 10.1177/0333102412455710"/>
 <result pre="monoclonal CGRP antibody in development for the preventive treatment of" exact="migraine" post=". Curr Pain Headache Rep. ( 2015) 19: 6."/>
 <result pre="K Krause DN . CGRP as the target of new" exact="migraine" post="therapies—successful translation from bench to clinic . Nat Rev"/>
 <result pre="P . Ibuprofen or acetaminophen for the acute treatment of" exact="migraine" post="in children: a double-blind, randomized, placebo-controlled, crossover study ."/>
 <result pre="30. Hamalainen ML Hoppu K Santavuori P . Sumatriptan for" exact="migraine" post="attacks in children: a randomized placebo-controlled study. Do children"/>
 <result pre="attacks in children: a randomized placebo-controlled study. Do children with" exact="migraine" post="respond to oral sumatriptan differently from adults? Neurology ("/>
 <result pre="31. Bille B Ludvigsson J Sanner G . Prophylaxis of" exact="migraine" post="in children. Headache ( 1977) 17: 61– 3. 10.1111/j.1526-4610.1977.hed1702061.x"/>
 <result pre="GR Mahfelati F . Sodium valproate versus propranolol in paediatric" exact="migraine" post="prophylaxis. Eur J Paediatr Neurol. ( 2005) 9: 333–"/>
 <result pre="trial of propranolol versus sodium valproate for the prophylaxis of" exact="migraine" post="in pediatric patients . Paediatr Drugs ( 2010) 12:"/>
 <result pre="Mccrory DC Gabapentin or pregabalin for the prophylaxis of episodic" exact="migraine" post="in adults. Cochr Database Syst Rev. ( 2013) CD010609."/>
 <result pre="CGRP levels in peripheral blood as a biomarker for chronic" exact="migraine" post=". Neurology ( 2013) 81: 1191– 6. 10.1212/WNL.0b013e3182a6cb72 23975872"/>
 <result pre="194: 451– 91. 10.1007/978-3-540-79090-7_13 45. Silberstein SD . Topiramate in" exact="migraine" post="prevention. Headache ( 2005) 45 ( Suppl. 1): S57–"/>
 <result pre="JR Lewis DW Schmitt J et al. . Topiramate for" exact="migraine" post="prevention: a randomized controlled trial. JAMA ( 2004) 291:"/>
 <result pre="SD Neto W Schmitt J Jacobs D . Topiramate in" exact="migraine" post="prevention: results of a large controlled trial. Arch Neurol."/>
 <result pre="SL Jordan DM Fisher AC Hulihan J . Topiramate for" exact="migraine" post="prevention in children: a randomized, double-blind, placebo-controlled trial ."/>
 <result pre="receptor alpha6 expression in the trigeminal ganglion alters inflammatory TMJ" exact="hypersensitivity" post=". Neuroscience ( 2012) 213: 179– 90. 10.1016/j.neuroscience.2012.03.059 22521829"/>
 <result pre="changes associated with antiepileptic mood stabilizers in the treatment of" exact="bipolar disorder" post=". Eur J Clin Pharmacol. ( 2018) 74: 1485–"/>
 <result pre="Pavone P Verrotti A Lubrano R et al. . Headache," exact="migraine" post="and obesity: an overview on plausible links. J Biol"/>
</results>
